With Merck’s vaccine efficacy pretensions circling the drain, and a coalition of leading plaintiff’s lawyers already in discovery in a fraud suit involving Gardasil, Vaccine Division President Julie Gerberding sells over half her Merck shares for $9.1 Million. Does she know something we don’t?